ArticlePharmaceuticals (Basel, Switzerland)2022
Design and Development of Levodopa Loaded Polymeric Nanoparticles for Intranasal Delivery.
Article in Pharmaceuticals (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- A Sustainable Adhesive Paradigm: Reversibly Reinforcing, Heat-Free Bonding with Universal Substrates.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Carvacrol-based nanoemulsions loaded with dimethyl fumarate intended for nose to brain delivery for treatment of multiple sclerosis.Drug delivery and translational research · 2026Article
- The Nasal Route Redefined: The Impact of Chitosan Nanoparticles on Drug Delivery.Mini reviews in medicinal chemistry · 2026Review
- Nanotherapeutics Mediated Intranasal Delivery for Therapeutic Effect on Parkinson's Disease: Balancing Advancements and Challenges.Current drug research reviews · 2026Review
- Expanding the Arsenal of Nanocarriers Against Parkinson Disease: Success so Far Roads Ahead.AAPS PharmSciTech · 2025Review
- Polymeric Nanocarrier-Based Drug Formulations for Enhancing Nose-to-Brain Delivery.Pharmaceutics · 2025Review
- Targeted Fluoxetine Delivery Using Folic Acid-Modified PLGA Nanoparticles for Selective Uptake by Glioblastoma Cells.Pharmaceutics · 2025Article
- Revamping Parkinson's disease therapy using PLGA-based drug delivery systems.NPJ Parkinson's disease · 2025Review
- Gellan Gum-Based In Situ Hydrogels for Nasal Delivery of Polymeric Micelles Loaded with Risperidone.Gels (Basel, Switzerland) · 2025Article
- Article
- Nose-to-brain Drug Delivery System: An Emerging Approach to Chemotherapy-induced Cognitive Impairment.Pharmaceutical nanotechnology · 2025Review
- Article
- Quality-by-design-engineered mitochondrial targeted nanoparticles for glioblastoma therapy.RSC advances · 2024Article
- Multilayer Nanocarrier for the Codelivery of Interferons: A Promising Strategy for Biocompatible and Long-Acting Antiviral Treatment.Pharmaceutics · 2024Article
- Intranasal Polymeric and Lipid-Based Nanocarriers for CNS Drug Delivery.Pharmaceutics · 2023Review
- Spray Dried Levodopa-Doped Powder Potentially for Intranasal Delivery.Pharmaceutics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Intranasal delivery is an alternative administration route to deliver levodopa (L-Dopa) to the brain. This drug delivery route offers high drug permeability across the nasal epithelium and rapid absorption into the central nervous system (CNS) while bypassing first-pass metabolism. In this study, we developed a library of polymeric nanocarrier systems for L-Dopa utilising poly(lactic-co-glycolic acid) (PLGA) and chitosan. A total of three PLGA nanoparticles formulations (P1, P2 and P3) were prepared using a modified water-in-oil-in-water (W/O/W) solvent evaporation technique, while four formulations of chitosan nanoparticles (C1, C2, C3 and C4) were prepared by ionic gelation method with sodium tripolyphosphate (TPP) as a cross-linking agent. Upon characterising nanocarriers developed, it was discovered that C2 demonstrated the best results with regard to droplet size (553 ± 52 nm), polydispersity index (0.522), zeta potential (+46.2 ± 2.3 mV), and encapsulation efficiency (82.38% ± 1.63). Transmission electron microscopy (TEM) and scanning electron microscopy (SEM) further corroborated the particle size analysis highlighting that C2 displayed uniform particle size with spherical morphology. Additionally, X-ray diffraction analysis (XRD) revealed that C2 was in an amorphous state while Fourier transform infrared (FTIR) analysis showed that there were no chemical interactions that might change the chemical structure of L-Dopa within the polymeric nanoparticle matrix. Lastly, an in-vivo intranasal study in male Wistar rats showed that the absorption of L-Dopa when formulated as chitosan nanoparticles was significantly enhanced (p < 0.05) by approximately two-fold compared to unmodified L-Dopa. Therefore, this work illustrates that formulating L-Dopa into chitosan nanoparticles for intranasal delivery is a potentially viable formulation strategy to improve the bioavailability of the drug for the treatment of Parkinson’s disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.